Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Myelodysplastic Syndromes 3Leukemia, Myelomonocytic, Chronic 3Leukemia, Myeloid, Acute 2Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Leukemia, Biphenotypic, Acute 1Carcinoma, Squamous Cell 1

Interventions

pembrolizumab 61Cisplatin 45Cetuximab 32Radiotherapy 25Nivolumab 22Docetaxel 16Radiotherapy, Intensity-Modulated 14Paclitaxel 13Carboplatin 13durvalumab 11Radiation 10Fluorouracil 10Magnetic Resonance Spectroscopy 9Cyclophosphamide 9fludarabine 8Erlotinib Hydrochloride 8budigalimab 7Ipilimumab 7atezolizumab 6Radiosurgery 6Gemcitabine 6Drug Therapy 6130-nm albumin-bound paclitaxel 6tremelimumab 5tislelizumab 5spartalizumab 5fludarabine phosphate 5avelumab 5Surgical Procedures, Operative 5Specimen Handling 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Squamous Cell Carcinoma of Head and Neck × cedazuridine × Clear all
NCT06357858 2024-07-03

ASTX727 and Nivolumab in Squamous Cell Carcinoma of the Head and Neck

Case Comprehensive Cancer Center

Phase 1 Withdrawn
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡